Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 933 matching trials from the live ClinicalTrials.gov search.
Conditions
Age-Related Macular Degeneration
Interventions
0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
Conditions
Uveitis, Vasculitis, Ocular Inflammatory Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Wet Age-related Macular Degeneration
Interventions
NeoVista Ophthalmic System
Device
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • San Antonio, Texas
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Conditions
Dry Age Related Macular Degeneration.
Interventions
Retinal transplantation instrument, Fetal tissue.
Device
Lead sponsor
Radtke, Norman D., M.D.
Individual
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
i-Lumen AMD
Device
Lead sponsor
i-Lumen Scientific AUS PTY LTD
Industry
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Poway, California • Manchester, Connecticut • Lemont, Illinois + 4 more
Completed No phase listed Observational Accepts healthy volunteers

Lucentis for Treatment of Macular Edema

NCT00464581
Conditions
Cystoid Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Up to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Macular Degeneration
Interventions
Ranibizumab
Biological
Lead sponsor
Xbrane Biopharma AB
Industry
Eligibility
50 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Ranibizumab 0.5mg, Aflibercept 2.0mg
Drug
Lead sponsor
Arshad Khanani
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Reno, Nevada
Conditions
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Interventions
Not listed
Lead sponsor
Splice Bio
Industry
Eligibility
12 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
San Diego, California • Aurora, Colorado • Gainesville, Florida + 10 more
Conditions
Cataract, Macular Degeneration, Glaucoma
Interventions
Technology-based Eye Care Services (TECS) Protocol
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Not listed No phase listed Observational Accepts healthy volunteers

Ultrasonic Evaluation of Ocular Tissues

NCT00279695
Conditions
Glaucoma, Tumors, Age-Related Macular Degeneration
Interventions
high frequency ultrasound examination
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Age Related Maculopathy, Retinal Degeneration
Interventions
Eccentric Viewing Training for Reading
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
La Jolla, California • Redlands, California • Santa Maria, California + 44 more
Conditions
Age-Related Macular Degeneration
Interventions
AG-013,958
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more
Active, not recruiting Phase 2 Interventional Results available

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

NCT03933904
Conditions
Castleman Disease, Castleman's Disease, Multicentric
Interventions
Sirolimus
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
2 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Little Rock, Arkansas • Philadelphia, Pennsylvania
Conditions
Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
Interventions
i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
Device
Lead sponsor
i-Lumen Scientific, Inc.
Industry
Eligibility
50 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

NCT03318549
Conditions
Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
Interventions
Visual Performance tests, Brain-computer interface
Diagnostic Test · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Miami, Florida
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
ACU-4429, Matching placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
Conditions
Macular Degeneration, Central Visual Impairment
Interventions
Personalised Remapping Training, RSVP personalized remappi, Reading text in the wild with remapping
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Edina, Minnesota
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Uveitic Cystoid Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Miami, Florida • Palm Beach Gardens, Florida
Conditions
"Wet" Age-Related Macular Degeneration
Interventions
Squalamine Lactate
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
29
States / cities
Beverly Hills, California • Louisville, Colorado • Boynton Beach, Florida + 24 more